Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
GOSS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.50 - $1.55
Previous CloseN/A
Volume602.63K
Average Volume (3M)1.78M
Market Cap
$290.84M
Enterprise Value$113.35M
Total Cash (Recent Filing)$65.24M
Total Debt (Recent Filing)$222.46M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 13, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding227,221,270
10 Day Avg. Volume1,611,567
30 Day Avg. Volume1,776,654
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.75
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$8.75Price Target Upside583.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Gossamer Bio News
PremiumCompany Announcements
Gossamer Bio Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionUpcoming expansion into PH-ILD may unlock blockbuster potential, in the view of the management.
Strategic CollaborationThe strategic collaboration with Chiesi for the co-development and commercialization of seralutinib in PAH and PH-ILD further validates the potential of the program and strengthens its financial position.
Therapeutic InnovationSeralutinib, an inhaled tyrosine kinase inhibitor, is poised to redefine the treatment landscape for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Bears Say
Clinical Trial EnrollmentSignals detected with seralutinib from TORREY could be real, and the company has the potential to eke out a win, assuming GOSS enrolls more severe patients in Phase 3 PROSERA.
Investor SentimentInvestor sentiment on GOSS has greatly contracted following Phase 2 TORREY data, making some wonder if the company can pull off a win.
Phase 2 Trial ResultsThe topline Ph.2 TORREY study data disappointed, although there were encouraging signals in severe patients.
---
Ownership Overview
9.39% Insiders
9.72% Mutual Funds
45.40% Other Institutional Investors
29.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.50 and its highest was $1.55 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Gossamer Bio Inc’s market cap is $290.84M.
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is May 13, 2025 which is in 48 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Mar 13, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.02.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -0.19.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 227,221,270 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 11.538%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Currently, no hedge funds are holding shares in GOSS
---
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (583.59% Upside)
$8.75 (583.59% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 368.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.18%
12-Months-Change
Fundamentals
Return on Equity
-122.54%
Trailing 12-Months
Asset Growth
1.08%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
---
GOSS Stock 12 Month Forecast
Average Price Target
$8.75
▲(583.59% Upside)
Technical Analysis
Best Analysts Covering GOSS
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-1.60%
reiterated a buy rating 13 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -1.60% per trade.
---